Skip to content

Discriminative Validity of Strain Elastography of the Supraspinatus Tendon

Discriminative Validity of Real-time Sonoelastography of the Supraspinatus Tendon: Comparison of Findings Between Patients With Supraspinatus Tendinopathy and Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03425344
Enrollment
60
Registered
2018-02-07
Start date
2018-03-11
Completion date
2019-08-21
Last updated
2019-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elasticity Imaging Techniques, Musculoskeletal Disease, Rotator Cuff Tendinitis, Tendinopathy

Brief summary

This study aims at testing the discriminative validity of strain elastography in the normal and abnormal/pathological Supraspinatus tendon due to tendinopathy

Detailed description

The case-control trial will include 96 participants. 48 of them diagnosed with supraspinatus tendinopathy by MRI and 48 healthy subjects. In this study the investigators will compare the outcome of tissue elasticity measured by sonoelastography, with MRI and conventional ultrasound. Patients will be recruited through different radiology department and healthy volunteers will be recruited primarily through advertising in local newspapers and social media.

Interventions

DIAGNOSTIC_TESTDiagnostic

No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..

Sponsors

Odense University Hospital
CollaboratorOTHER
Sygehus Lillebaelt
CollaboratorOTHER
Gigtforeningen
CollaboratorOTHER
Region of Southern Denmark
CollaboratorOTHER
Radiograf Rådet
CollaboratorUNKNOWN
Karen Brage
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

A case-control study without intervention

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index \< 30 * Symptomatic: Positive on 3/5 clinical tests (full can, empty can, resisted external rotation, neers, hawkins. * Asymptomatic: No shoulder pain in the last year, negative on 5/5 clinical tests (full can, empty can, resisted external rotation, neers, hawkins).

Exclusion criteria

* Shoulder-fracture, operation and luxation, known-neuromuscular disease, rheumatoid arthritis, cancer, fibromyalgia, spondyloarthropathy and psychiatric disorders, pregnancy and inability to read and understand Danish. Biceps rupture, labrum lesions, supraspinatus tears (\> 1/3 of the vertical tendon height) and calcifications (\> 2 mm in length) (MRI).

Design outcomes

Primary

MeasureTime frameDescription
Tendon quality (SEL)BaselineSonoelastography - strain elasticity

Secondary

MeasureTime frameDescription
Pain on a VAS scaleBaselineChange from baseline in Visual Analogue Scale (VAS). Ranging from 0 to 10; 0 being no pain and 10 being severe pain.
Quality of life on the E!-5D-3L questionnaireBaselineChange in Euro Qol 5D index (EQ-5D-3L). The system consists of a descriptive system and a visual analogue scale (EQ VAS). The descriptive system contains 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 3 levels; no problems, some problems and extreme problems. The EQ-VAS range from 0 (worst imaginable health state) to 100 (best imaginable health state).
Tendon quality (MRI)BaselineMagnetic Resonance
Tendon quality (US)BaselineConventional ultrasound
DisabilityBaselineChange in Disability of the Arm, Shoulder and Hand questionnaire (DASH). Each item is rated with a score from 1 (least disability) to 5 (most disability). All scores are added together, producing a raw score, which is then transformed into a score of 100 maximum. A higher score indicates greater disability.

Other

MeasureTime frameDescription
DemographicBaselineGender, age, bmi, education (level), duration of symptoms, symptom history

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026